ProtoKinetix, Incorporated
Moat Score — ProtoKinetix, Incorporated
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Protagonist's proprietary platform for engineering structurally constrained peptides has produced two separate billion-dollar-class partnerships (Takeda, Johnson & Johnson), strong evidence of defensible, hard-to-replicate platform IP rather than a one-off molecule. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As an R&D-intensive, pre-commercial biopharma with no owned manufacturing, Protagonist has no cost advantage - it relies on third-party CMOs and CROs like most peptide/biotech peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Favorable royalty tiers (6-17%) and a profit-sharing structure on rusfertide reflect real negotiating leverage with large pharma partners, earned by platform strength, though Protagonist does not control end-market drug pricing itself. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in peptide drug discovery and licensing. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Takeda and J&J have each invested years and hundreds of millions of dollars into co-developing rusfertide and icotrokinra respectively, making it operationally and financially costly for either partner to walk away at this late stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The peptide-therapeutics space is competitive and well-funded industry-wide, so scale alone does not strongly deter new entrants, though replicating a validated platform with two late-stage partnered assets would take years. |